Ontology highlight
ABSTRACT: Impact statement
The high mortality of non-small cell lung cancer (NSCLC) is mainly because the cancer has progressed to a more advanced stage before diagnosis. If NSCLC can be diagnosed at early stages, especially stage 0 or I, the overall survival rate will be largely improved by definitive treatment such as lobectomy. We herein validated two novel circulating serum ExmiRs as diagnostic biomarkers for early-stage NSCLC to fulfill the unmet medical need. Considering the number of specimens in this study, circulating serum exosomal miR-20b-5p and miR-3187-5p are putative NSCLC biomarkers, which need to be further investigated in a larger randomized controlled clinical trial.
SUBMITTER: Zhang ZJ
PROVIDER: S-EPMC7553089 | biostudies-literature | 2020 Oct
REPOSITORIES: biostudies-literature
Zhang Zhi-Jun ZJ Song Xing-Guo XG Xie Li L Wang Kang-Yu KY Tang You-Yong YY Yu Miao- M Feng Xiao-Dong XD Song Xian-Rang XR
Experimental biology and medicine (Maywood, N.J.) 20200802 16
<h4>Impact statement</h4>The high mortality of non-small cell lung cancer (NSCLC) is mainly because the cancer has progressed to a more advanced stage before diagnosis. If NSCLC can be diagnosed at early stages, especially stage 0 or I, the overall survival rate will be largely improved by definitive treatment such as lobectomy. We herein validated two novel circulating serum ExmiRs as diagnostic biomarkers for early-stage NSCLC to fulfill the unmet medical need. Considering the number of specim ...[more]